natgillin/translations-raw huggingface dataset:
afsnit 6) hvis du bruger anden medicin, der opløser blodpropper, såsom vævsplasminogenaktivator.
if you are allergic to defibrotide or other ingredients of this medicine (listed in section 6) if you are using other medicines to break down blood clots such as tissue plasminogen activator
Afsprit gummipropperne med alkoholservietter, og lad dem tørre inden brug.
Clean the rubber stoppers on the vials with alcohol swabs and allow them to dry before use.
Afspritningsservietter
Alcohol wipes
afspritningsservietter eller lignende
alcohol wipes or similar.
afspritningsservietter eller lignende.
alcohol wipes or similar.
Afstand fra behandlings- krævende væv
Distance from target tissue
Afstanden mellem to injektioner bør ikke være kortere end én måned.
The interval between two injections should not be shorter than one month.
Afstødning af lever- og nyre- transplantat, Vogt-Koyanagi- Hadaras syndrom
Liver and renal graft rejection, Vogt- Koyanagi- Harada disease
Afstødning af nyre- og levertransplantat
Kidney and liver graft rejection
Afstødning af nyretransplantat medfører ingen ændringer af MPAs farmakokinetik; dosisreduktion eller afbrydelse af CellCept er ikke nødvendig.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of CellCept is not required.
Afstødning af nyretransplantat medfører ingen ændringer af MPA’s farmakokinetik; dosisreduktion eller afbrydelse af CellCept er ikke nødvendig.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of CellCept is not required.
Afstødning af nyretransplantat medfører ingen ændringer af MPA’s farmakokinetik; dosisreduktion eller afbrydelse af CellCept er ikke nødvendig..
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of CellCept is not required.
Afstødning af nyretransplantat medfører ingen ændringer af MPA’s farmakokinetik; dosisreduktion eller afbrydelse af Myclausen er ikke nødvendig.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Myclausen is not required.
Afstødning af nyretransplantat medfører ingen ændringer af MPA’s farmakokinetik; dosisreduktion eller afbrydelse af Mycophenolate mofetil Teva er ikke nødvendig.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Mycophenolate mofetil Teva is not required.
Afstødning af nyretransplantat medfører ingen ændringer af MPA’s farmakokinetik; dosisreduktion eller afbrydelse af Mycophenolate mofetil Teva er ikke nødvendig.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dose reduction or interruption of Mycophenolate mofetil Teva is not required.
Afstødning af nyretransplantat medfører ingen ændringer af MPA’s farmakokinetik; dosisreduktion eller afbrydelse af Myfenax er ikke nødvendig.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Myfenax is not required.
Afstødning af nyretransplantat medfører ingen ændringer af MPA’s farmakokinetik; dosisreduktion eller afbrydelse af Myfenax er ikke nødvendig.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dose reduction or interruption of Myfenax is not required.
afstødning af transplanteret knoglemarv (graft versus host-sygdom)
rejection of transplanted bone marrow (graft versus host disease)
Afstødning af transplanteret knoglemarv (grav versus host-sygdom)
rejection of transplanted bone marrow (graft versus host disease)
afstødning af transplanteret knoglemarv;
rejection of transplanted bone marrow;
Afstødningsbehandling efter andre allotransplantater
Treatment of allograft rejection after transplantation of other allografts
Afstødningsbehandling efter hjertetransplantation
Treatment of allograft rejection after heart transplantation
Afstødningsbehandling efter nyre- eller levertransplantation
Treatment of allograft rejection after kidney or liver transplantation
Afsæt kromatografistrimlens startpunkt, midtlinje og væskefront med blyant som vist nedenfor:
Mark the chromatographic strip for origin, mid and solvent front lines with a pencil as shown below:
Aftag den udvendige og indvendige beskyttelseshætte på kanylen.
Remove the outer and inner needle protection caps.
Aftagelig beskyttelsesfilm
Release liner
Aftagelig beskyttelsesfilm: Transparent fluoropolymerovertrukken polyesterfilm.
Release liner: Transparent fluoropolymer coated polyester film.
Aftagelig beskyttende film: polyesterfilm, fluoropolymerbelagt
Release liner: polyester film, fluoropolymer-coated.
aftagelig kanyle
removable needle
AFTAGELIGE KLISTERMÆRKER TIL DIN PERSONLIGE KALENDER
PEEL-OFF STICKERS FOR YOUR PERSONAL CALENDAR
Aftagning
Removal
Aftagning og bortskaffelse af nålen
Remove and discard the needle
Aftendosis
Evening Dose
AFTOVAXPUR DOE
EU/2/13/153/351
AFTOVAXPUR DOE
Number
AFTOVAXPUR DOE injektionsvæske, emulsion til kvæg, får og svin.
AFTOVAXPUR DOE emulsion for injection for cattle, sheep and pigs
Aftør det område, du vil injicere i, med den medfølgende spritserviet.
Wipe the area that you will inject with the alcohol swab provided.
Aftør grundigt.
Dry thoroughly.
Aftør gummiforseglingen med en desinfektions- serviet.
Wipe the Rubber Seal with an alcohol swab.
Aftør gummiforseglingen med en desinfektionsserviet.
Wipe the rubber seal with a swab.
Aftør gummiforseglingen med en desinfektionsserviet.
Wipe the Rubber Seal with an alcohol swab.
Aftør huden med en desinfektionsserviet, og lad huden tørre, før du indsprøjter din dosis.
Wipe your skin with an alcohol swab, and let the injection site dry before you inject your dose.
Aftør huden med en desinfektionsserviet, og lad huden tørre, før du indsprøjter din dosis.
Wipe your skin with an alcohol swab, and let your skin dry before you inject your dose.
Aftør huden på injektionsstedet i cirklende bevægelser med en spritserviet.
Wipe your injection site with an alcohol swab in a circular motion.
Aftør ikke blisteråbningen.
Do not wipe the blister slot
Aftør kun TOPPEN og YDERSIDEN af hoveddelen.
Wipe only the TOP and OUTSIDE surfaces of the Base.
Aftør omhyggeligt.
Dry thoroughly.
Aftør stedet, hvor Nplate skal injiceres, med en sprittampon og med en cirkulær bevægelse.
Wipe the site where Nplate is to be injected with an alcohol swab, using a circular motion.
Aftør toppen af hætteglasset med en desinfektionsserviet.
Wipe the top of the vial with an alcohol swab.
Aftør toppen på hætteglasset med rekonstitueret suspension med en steril spritserviet.
Wipe the top of the vial of the reconstituted suspension with a sterile alcohol swab.
Aftør ydersiden af FORSTEO-pennen med en fugtig klud.
Wipe the outside of the FORSTEO with a damp cloth.
Afvejningen af fordele og risici (benefit/risk- forholdet) fremgår af afsnittet om den videnskabelige drøftelse i denne EPAR.
The benefit-risk balance may be found in the scientific discussion module of this EPAR.
Afvejningen af fordele og risici (benefit/risk-forholdet) fremgår af afsnittet med den videnskabelige drøftelse i denne EPAR.
The benefit-risk balance may be found in the scientific discussion module of this EPAR.
Afvent 2 uger for at vurdere virkningen af denne og evt. efterfølgende dosisjusteringer♦.
Wait 2 weeks to assess the effects of this and any subsequent dose adjustments♦.
Afvent 2 uger for at vurdere virkningen af dette og evt. efterfølgende dosisjusteringer.
Wait 2 weeks to assess the effects of this and any subsequent dose adjustments.
Afvigelse fra baseline sammenlignet med placebo (p-værdi)
Compared to Placebo (p-value)
Afvigelse fra placebo (justeret gennemsnit) (95 % CI)
Difference from placebo (adjusted mean) (95% CI)
Afvigelser fra den ovenfor angivne doseringer tilrådes ikke ,
Deviations from the posology indicated above are not advised.
Afvigelser i analyser for leverfunktionen
Disturbance in liver function tests
Afvigelser i hjertefunktionen
Heart abnormalities
Afvigelser i laboratorieundersøgelser
Laboratory test abnormalities
Afvigelser i laboratorieværdier
Laboratory test abnormalities Haematology
Afvigelsesestimat [95% KI]d
Difference estimate [95% CI]d
Afvigende brug af veterinærlægemidlet fra det som er beskrevet i produktresumeet (SPC’et) kan øge forekomsten af resistente bakterier over for flouroquinoloner og kan muligvis nedsætte effekten af behandling med andre fluoroquinoloner grundet mulig kryds-resistens.
Use of the veterinary medicinal product deviating from instructions given in the summary of product characteristics (SPC) may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other fluoroquinolones due to the potential for cross- resistance.
Afvænning
Weaning
Afvænning skal som et minimum forsøges hver 12. time, når patienten er stabil på en lav dosis INOmax.
Weaning should be attempted at least every 12 hours when the patient is stable on a low dose of INOmax.
Afvænningsp eriode
EU/2/12/145/001
Agalsidase alfa katalyserer hydrolysen af Gb3, idet det fjerner en terminal galaktose-rest fra molekylet.
Agalsidase alfa catalyses the hydrolysis of Gb3, cleaving a terminal galactose residue from the molecule.
Agalsidase beta er en rekombinant form af human -galaktosidase og fremstilles ved rekombinant DNA-teknologi ud fra en ovariecellekultur fra kinesiske hamstere (CHO).
Agalsidase beta is a recombinant form of human -galactosidase A and is produced by recombinant DNA technology using a mammalian Chinese Hamster Ovary (CHO) cell culture.
AGATE-1 –behandlingsnaive eller pegIFN + RBV- erfarne patienter med kompenseret cirrose
AGATE-1 –treatment-naïve or pegIFN +RBV experienced patients with compensated cirrhosis
Agenerase 15 mg/ml oral opløsning
Agenerase 15 mg/ml oral solution
Agenerase 15 mg/ml oral opløsning
Agenerase 15 mg/ml oral solution.
Agenerase 150 mg bløde kapsler
Agenerase 150 mg soft capsules
Agenerase 150 mg bløde kapsler
Agenerase 150 mg soft capsules.
Agenerase 150 mg bløde kapsler Amprenavir
Agenerase 150 mg soft capsules Amprenavir
Agenerase 150 mg bløde kapsler findes i plastbeholdere med 240 bløde kapsler.
Agenerase 150 mg soft capsules are supplied in plastic bottles containing 240 soft capsules.
Agenerase 50 mg bløde kapsler
Agenerase 50 mg soft capsules
Agenerase 50 mg bløde kapsler
Agenerase 50 mg soft capsules.
Agenerase 50 mg bløde kapsler Amprenavir
Agenerase 50 mg soft capsules Amprenavir
Agenerase 50 mg bløde kapsler findes i plastbeholdere med 480 bløde kapsler.
Agenerase 50 mg soft capsules are supplied in plastic bottles containing 480 soft capsules.
Agenerase blev oprindelig godkendt "under særlige omstændigheder", da der af faglige årsager på godkendelsestidspunktet kun forelå begrænsede oplysninger.
Agenerase was originally authorised under ‘Exceptional Circumstances’, because, for scientific reasons, limited information was available at the time of approval.
Agenerase bruges til HIV-1-inficerede voksne og børn over 4 år, som tidligere har fået protease- hæmmere.
Agenerase is used in protease inhibitor experienced HIV-1 infected adults and children above the age of 4 years.
Agenerase kapsler (uden samtidig brug af ritonavir) er studeret hos patienter med nedsat leverfunktion.
Agenerase capsules (without the boosting effect of ritonavir) have been studied in patients with liver impairment.
Agenerase kapsler indeholder vitamin E (109 IU/150 mg kapsel), derfor anbefales ekstra vitamin E- tilskud ikke.
Agenerase capsules contain vitamin E (109 IU/150 mg capsule), therefore additional vitamin E supplementation is not recommended.
Agenerase kapsler indeholder vitamin E (36 IU/50 mg kapsel), derfor anbefales ekstra vitamin E- tilskud ikke.
Agenerase capsules contain vitamin E (36 IU/50 mg capsule), therefore additional vitamin E supplementation is not recommended.
Agenerase kapsler skal synkes hele med vand eller anden drikke.
Agenerase capsules should be swallowed whole with water or another drink.
Agenerase må ikke administreres samtidig med lægemidler med smalt terapeutisk vindue indeholdende aktive stoffer, der er substrater for cytochrome P4503A4 (CYP3A4).
Agenerase must not be administered concurrently with medicinal products with narrow therapeutic windows containing active substances that are substrates of cytochrome P450 3A4 (CYP3A4).
Agenerase oral opløsning bør ikke anvendes, hvis du lider af en leversygdom.
Agenerase oral solution should not be used if you suffer from any liver disease.
Agenerase oral opløsning kan tages med eller uden mad.
Agenerase oral solution can be taken with or without food.
Agenerase oral opløsning, i kombination med andre antiretrovirale midler, er indiceret til behandling af HIV-1-inficerede voksne og børn over 4 år, som tidligere er behandlet med proteasehæmmere (PI’er).
Agenerase oral solution, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (PI) experienced HIV-1 infected adults and children above the age of 4 years.
Agenerase, i kombination med andre antiretrovirale midler, er indiceret til behandling af HIV-1- inficerede voksne og børn over 4 år, som tidligere er behandlet med proteasehæmmere (PI’er).
Agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (PI) experienced HIV-1 infected adults and children above the age of 4 years.
Agenerase, i kombination med andre antiretrovirale mindler, er indiceret til behandling af HIV-1- inficerede voksne og børn over 4 år, som tidligere er behandlet med proteasehæmmere (PI’er).
Agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (PI) experienced HIV-1 infected adults and children above the age of 4 years.
Agenerases udseende og pakningsstørrelse
What Agenerase looks like and contents of the pack
Agenerases udseende og pakningsstørrelse
What Agenerase looks like and the contents of the pack
Agenter, der kan overføres
Transmissible agents
Agentures Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved EndolucinBeta opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP concluded that the benefits of EndolucinBeta outweigh the risks and recommended that it be given marketing authorisation.
Agenturets Udvalg for Humanmedicinske lægemidler (CHMP) konkluderede, at fordelene ved Zurampic opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zurampic’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Advocate opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Advocate’s benefits are greater than its risks and recommended that Advocate be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Aivlosin opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Aivlosin’s benefits are greater that its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Bravecto opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Bravecto’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved BTVPUR opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that BTVPUR’s benefits are greater that its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Clomicalm opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Clomicalm’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Draxxin opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Draxxin’s benefits are greater than its risks and recommended that it be approved in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Eravac opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Eravac’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Evalon opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Evalon’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Fortekor Plus opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) decided that Fortekor Plus’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Imrestor opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Imrestor’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Letifend opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Letifend’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Metacam opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Metacam’s benefits are greater than its risks and they recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved MS-H Vaccine opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that MS-H Vaccine’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Porcilis PCV ID opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Porcilis PCV ID’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Poulvac E. coli opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Poulvac E. coli’s benefits are greated that its risks and recommended that it be approved in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Profender opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Profender’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Reconcile opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Reconcile’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved SevoFlo opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that SevoFlo’s benefits are greater that its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Simparica opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Simparica’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Suvaxyn Circo+MH RTU opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Suvaxyn Circo+MH RTU’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Vectormune ND opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Vectormune ND’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Velactis opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Velactis’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved ZACTRAN opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that ZACTRAN’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Zulvac SBV opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Zulvac SBV’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Zycortal opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Zycortal’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) afgjorde, at fordelene ved Adempas opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Adempas’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) afgjorde, at fordelene ved Anoro overstiger risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Anoro’s benefits are greater than its risks and recommended that it be approved for use in the EU.